🇺🇸 FDA
Pipeline program

DIPHENHYDRAMINE, METHYLPREDNISOLONE, PARACETAMOL, ublituximab, Ublituximab, ublituximab, CETIRIZINE, DEXAMETHASONE

TG1101-RMS-SC101

Phase 1 small_molecule active

Quick answer

DIPHENHYDRAMINE, METHYLPREDNISOLONE, PARACETAMOL, ublituximab, Ublituximab, ublituximab, CETIRIZINE, DEXAMETHASONE for Relapsing multiple sclerosis, Myasthenia Gravis is a Phase 1 program (small_molecule) at TG THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
TG THERAPEUTICS, INC.
Indication
Relapsing multiple sclerosis, Myasthenia Gravis
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials